Table 1.
Patient demographic and clinical characteristics at the time of cardiovascular magnetic resonance re‐conduction
|
All patients n = 27 | |
|---|---|
| Age (years) | 49.9 ± 11.8 |
| Male gender, n (%) | 16 (59.3%) |
| Organ of sarcoidosis' histological confirmation, n (%) | |
| Lung | 15 (55.6%) |
| Lymph node | 7 (25.9%) |
| Skin | 3 (11.1%) |
| Kidney | 1 (3.7%) |
| Central nervous system | 1 (3.7%) |
| Pulmonary function parameters | |
| FEV1 (L) | 3.0 ± 1.0 |
| FEV1 (% predicted) | 92.9 ± 19.3 |
| RV (L) | 2.1 ± 0.5 |
| RV (% predicted) | 105.6 ± 22.1 |
| R tot (kPa·s/L) | 0.24 ± 0.10 |
| R tot (% predicted) | 79.2 ± 35.1 |
| IVC (L) | 3.9 ± 1.2 |
| IVC (% predicted) | 94.4 ± 15.8 |
| TLC (L) | 6.0 ± 1.3 |
| TLC (% predicted) | 96.0 ± 11.5 |
| DLco (mmol/min/kPa) | 7.0 ± 2.2 |
| DLco (% predicted) | 72.6 ± 15.4 |
| DLco/VA (mmol/min/kPa/L) | 1.4 ± 0.2 |
| DLco/VA (% predicted) | 88.6 ± 14.2 |
| Capillary blood gas analysis | |
| pO2 (mmHg) | 78.2 ± 8.8 |
| pCO2 (mmHg) | 33.9 ± 4.0 |
| sO2 (%) | 95.6 ± 2.2 |
| Cardiovascular risk factors, n (%) | |
| Arterial hypertension | 11 (40.7%) |
| Diabetes mellitus | 4 (14.8%) |
| Dyslipidaemia | 12 (44.4%) |
| Obesity | 9 (33.3%) |
| BMI (kg/m2) | 29.3 ± 6.4 |
| Familial disposition | 10 (37.0%) |
| Continued nicotine consumption | 12 (44.4%) |
| Pack‐years | 6.0 ± 9.5 |
| Cardiac symptomatology, n (%)a | |
| Palpitation | 15 (55.6%) |
| Chest pain | 15 (55.6%) |
| Dizziness | 10 (37.0%) |
| Syncopal episodes | 0 (0.0%) |
| NYHA functional class, n (%) | |
| No limitations | 1 (3.7%) |
| I | 6 (22.2%) |
| II | 14 (51.9%) |
| III | 5 (18.5%) |
| IV | 1 (3.7%) |
| Cardiovascular medication use at CMR re‐conduction, n (%) | |
| Beta‐blocker | 8 (29.6%) |
| Bisoprolol | 5 (18.5%) |
| Metoprolol | 2 (7.4%) |
| Carvedilol | 1 (3.7%) |
| ACE inhibitor | 9 (33.3%) |
| Angiotensin II receptor blocker | 1 (3.7%) |
| Diuretics | 9 (33.3%) |
| Ivabradine | 2 (7.4%) |
| Amiodarone | 1 (3.7%) |
| Immunosuppressant use at CMR re‐conduction, n (%) | |
| Steroidal monotherapy | 10 (37.0%) |
| Azathioprine, combined with steroids | 2 (7.4%) |
| Methotrexate, combined with steroids | 1 (3.7%) |
| Immunosuppressant use since the initial, CS‐confirming CMR conduction, n (%) | |
| Steroidal monotherapy | 11 (40.7%) |
| Azathioprine, combined with steroids | 4 (14.8%) |
| Methotrexate, combined with steroids | 1 (3.7%) |
Data are presented as mean ± SD or total number and percentage (in parentheses), as appropriate.
ACE, angiotensin converting enzyme; BMI, body mass index; CMR, cardiovascular magnetic resonance; CS, cardiac sarcoidosis; DLco, diffusion capacity of the lung for carbon monoxide; FEV1, forced expiratory volume in first second of expiration; IVC, inspiratory vital capacity; NYHA, New York Heart Association; pCO2, carbon dioxide partial pressure; pO2, oxygen partial pressure; R tot, total resistance; RV, residual volume; sO2, oxygen saturation; TLC, total lung capacity; VA, alveolar volume.
Symptomatology refers to any time occurrence since the initial, CS‐confirming CMR conduction.